with that a our Thanks, set good But I We pleased quarter. extremely records commercial of third overall of we’re highlight number performance. want particularly quarter about. excited to three and basis everyone. product-by-product and Martine, milestones the these we’re during on morning, Overall, an
In the first which revenue a First, puts in us crossed for the effectively been a quarters, $XXX run in billion time million $X saying on $X couple we total fact have billion quarter, for rate. last revenues of at our rate. third our history, run the we’re that
on and Tyvaso, we patients approached Remodulin, treprostinil one mentioned, DPI, Martine as worldwide Second, of exceeded U.S. our and therapies, XX,XXX Tyvaso Orenitram. patients XX,XXX
revenue revenues million puts that the rate. Finally, billion a product run $XXX exceeded $X Tyvaso for which quarter, on annual
reached a rate the first basis. first that drug at quarters generates These have working the that our the blockbuster is considered for a effective affairs $X has know, least “blockbuster billion last to been sales commercial get help all So you status, annual time been Therapeutics in of many have we history, point. two product.” in a a of – the and on the United As be product are due year, medical to particularly efforts to hard but teams results who to run have us this widely
Tyvaso. bit color little the a provide of I’ll product starting level, Now, with at
really for said, by I a which reported was factors. number As of strong Tyvaso, a we driven quarter
removed. obstacle Medicare with First, the third quarter full coverage patients so has with first been was or quarter PH-ILD, CMS for that our prescribing
continuing ILD to having specialists, ILD their prescribers, patients those educate for PAH Second, particularly screen efforts is to our an impact.
prescribers to the base. And has big our continue grow number we driver grown a launch was Since the by finally, of XXXX, of XX%. DPI. approximately Third, the of prescriber Tyvaso Tyvaso beginning
we during result the quarter. added of things, XXX a these Tyvaso patients As
launch, then physician referrals, enthusiasm enthusiasm prescriptions Regarding launch, new product DPI space, some is in Tyvaso for term but see Often which new the it starts. and to engagement around and this takes product hear extremely patient is high. PAH a time around into translate our that we the for
from trend Fortunately, the the activity as referral strong has launch Tyvaso very been that bucked beginning. DPI has
out Tyvaso therapies. the For some new delivered our TD-XXX that around expect over we patient the between referral context, mix the Tyvaso eventually while we’ve and XX/XX patient nebulizer via is DPI mix Tyvaso in settle time, Meanwhile, the past are said class to DPI early, XX/XX. to to the expected. prostacyclin at we’re rate compared other discontinuation DPI already from while really Tyvaso of Also, by around transitions patients still as as TD-XXX occurring encouraged very low using
launched referral strong Remunity and Turning availability and of a to that to option The and distribution grow Remunity filled cassettes. total version over the and pump we’ve patients XXXX stability the we the proceeding throughout weekly relative pump. XXXX. a third generic introduced cassettes balance Remodulin of of competitors. broaden shipments In Offering options patient for their uptake filled patient to business, pre-filled both being Remunity Remodulin. expected expect year shipments September, pre-filled the own and quarter, pharmacy who In the of and basis starts receive the our than to patients saw is on fill is the relaunch and is despite accelerate The patterns patient the we option. we seen of and prefer into of for on monthly continuation filled complements well, resilience rather pump Remunity pre-filled of Remunity
adoption is in do Continued or pump patients becoming therapy. that the of Remunity increasingly to PAH delay important not their Remodulin a ensure disruption experience
would this our that is the our specialty inventory the other specialty patients X Remodulin pumps funded, parallel pumps the a down. as it as time, the prior delivery, to for CADD-MS winding manufacturer pharmacy on have X understanding Earlier Medical and the in pursued CADD-MS for was funded those therapy. to Smiths Remodulin X At pumps And several of hospitals ensure One may well and of pharmacy Remunity that we remaining and for at available MS thousand sold of inventory that in of additional discontinued pump partners the of pump both pump the that pumps, manufacturer X XXXX. United market we by our their subcutaneous and Therapeutics pumps in development hospitals. partners been the year, MS used have pumps is
the alternative Fortunately, market as patients. Remodulin the on and is Remunity available an subcutaneous pump for
transition IV of of demonstrated EXPEDITE therapeutic de with effects the study fewer top Class dose functional treatment X to released X study We patients and patient reach a and Orenitram. and that this side investigating can recent the PAH to Moving with faster, from from titration novo. This Orenitram. line Remodulin than Orenitram approach, starting Class rapid a Phase data
number Orenitram to normalized. term, from our wrap X,XXX prefer the EXPEDITE up, to or a and around armamentarium of be patients tap X,XXX one of of to the double market, on how established Orenitram two, to Tyvaso, patients to medications goal portfolio Remodulin a quickly The the To failed three, the PH-ILD these and Tyvaso physicians Over established of the protocol have patients. in after either provides to important treatment this in effectively that We with and into an PAH continue use as long will goal questions the frame ventricular we existence it. want has function oral roadmap around to transition market, right many year that expect the could of product XXXX. know, part we we last size of address end by from you
patients added – the referrals patient XXX scheduled to then are referrals for approval be patients in DPI. can around we new have Tyvaso through their start. at We XXX for the October, Specialty pending exclude has pharmacy end way alone. that and Tyvaso. XXX October than process making around As transition of patients TD-XXX X,XXX from more on the insurance referrals Those
around are sure months monthly greater average that DPI average three DPI November, XX% Our remain referrals the in may launch. each of the pre that they I’m pre should holidays, average. referrals than December Tyvaso with might above in the last monthly but drop
fair to get we’ve be we So to based mention X,XXX the I by especially that the said just because patients X,XXX holidays. to the well a it been year. therapy we’re say today patient delay Having the provided, Thanksgiving choose fourth relates we’re positioned around objectives think initiation sometimes tapped for quickly. clinician good to have accomplished. that into selling to the we’re of the reduces between and – which setting it’s end I stats momentum relatively shipping into Typically, it days, next patients can the new on a goal after patients, of heading that of really market, and there us demonstrating of Christmas, X,XXX continuing Thus, PH-ILD little the until Not days, our build Tyvaso and holidays, year, is once goal challenging quarter as and that, and days.
the I’ll So over lead with Martine the turn that, to to call Q&A session.
